The Intermountain Medical Center Heart Institute study is part of a larger study called faCTor-64, which is a landmark, randomized trial designed to determine if using CT scans to screen for heart disease in diabetic patients who don't have heart disease symptoms can help save lives.
As Intermountain researchers measured coronary artery plaque buildup in study participants, they discovered that a major controllable predictor of heart disease was BMI. Simply put: the greater the patient's BMI, the greater their risk for heart disease.
Researchers will present this study at the 2013 American Heart Association Scientific Sessions in Dallas, on Nov. 17 at 10 am, ET.
"Our study shows there's a strong linear relationship between BMI and plaque volume and composition," said J. Brent Muhlestein, MD, lead researcher and co-director of cardiovascular research at the Intermountain Medical Center Heart Institute in Murray, Utah. "So even being a little overweight is associated with more plaque, while being obese is associated with a lot of plaque."
Researchers say the findings are significant because heart disease causes about 75% of deaths in patients who have diabetes, but not everyone has obvious risk factors, such as smoking, high glucose levels, high cholesterol levels, or high blood pressure.
Patients with obvious risk factors can be treated, but for the patients who don't have obvious risk factors, their first indictor of heart disease is often in the form of a heart attack or stroke – or even death.
Current methods to measure plaque buildup are invasive and costly, and are not used to screen patients who don't display signs of heart disease. However, the coronary computed tomography angiography (CCTA) offers a new, and less invasive way to screen these patients for heart disease.
"It may be that in diabetic patients without any symptoms of heart disease, their BMI could be used to determine if they need a CT scan to screen for plaque buildup," said Muhlestein. "We could then develop a treatment plan for at-risk patients.
Findings from the study may also change the way diabetic patients are treated. Current diabetic management strategies include three options:
- Insulin-sensitizing medication to help the body's tissues become more sensitive to insulin and decrease glucose production
- Insulin-stimulating therapy to increase the pancreas' production of insulin
- Insulin injections
When patients are treated with insulin therapy and injections, they commonly experience weight gain. "When you provide more insulin, it's associated in almost every study with increased weight gain," said Dr. Muhlestein.
While weight gain does not necessarily predict heart disease in non-diabetics, the findings of this study shows that weight gain in diabetics can indicate the buildup of plaque. This is significant because the degree of weight gain can be reduced by using other types of diabetic treatments, such as insulin sensitizing medication.
"Based on the findings of this study, choosing insulin sensitizing therapy, as the primary management strategy in diabetic patients may be beneficial by reducing the tendency towards elevated BMI's, said Dr. Muhlestein.
Not only will the results of this study help researchers better understand which treatments will reduce weight gain, but they will also help researchers predict who will get heart disease – which will help physicians offer better long-term diabetic treatments to their patients.
"Our goal at the Intermountain Medical Center Heart Institute, is to learn how to predict who will get heart disease, so we can provide the best care possible and improve long-term outcomes – rather than waiting until a person has a heart attack or even dies," he said.
Other researchers involved in the study include: Alan C. Kwan, Heidi May, George Cater, Christopher T. Sibley, Boaz Rosen, Joao A.C. Lima, Donald Lappe, Jeffrey L. Anderson and David A. Bluemke.
Intermountain Heart Institute at Intermountain Medical Center is the most advanced heart program in the Intermountain West with highly specialized experts in all areas of heart care. Intermountain Medical Center is the flagship hospital for the Intermountain Healthcare system based in Salt Lake City.
Jess C. Gomez | EurekAlert!
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine